Search

Your search keyword '"CoMSIA"' showing total 1,321 results

Search Constraints

Start Over You searched for: Descriptor "CoMSIA" Remove constraint Descriptor: "CoMSIA"
1,321 results on '"CoMSIA"'

Search Results

301. In silico exploration of hydroxylated polychlorinated biphenyls as estrogen receptor β ligands by 3D-QSAR, molecular docking and molecular dynamics simulations.

302. In silico multiscale drug design to discover key structural features of potential JAK2 inhibitors.

304. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase:HQSAR, CoMSIA and molecular dynamics simulations

305. Studies on molecular mechanism between SHP2 and pyridine derivatives by 3D-QSAR, molecular docking and MD simulations

306. In silico design of novel PIN1 inhibitors by combined of 3D-QSAR, molecular docking, molecular dynamic simulation and ADMET studies.

307. Structural insights on 2-phenylquinazolin-4-one derivatives as tankyrase inhibitors through CoMFA, CoMSIA, topomer CoMFA and HQSAR studies.

308. Combination of 2D and 3D-QSAR studies on DAPY and DANA derivatives as potent HIV-1 NNRTIs.

309. A combined pharmacophore modeling, 3D-QSAR and molecular docking study of substituted bicyclo-[3.3.0]oct-2-enes as liver receptor homolog-1 (LRH-1) agonists.

310. Virtual Screening: Using Molecular Docking and 3D-QSAR Analysis of Matrix Metalloproteinase Inhibitors.

311. Cholesteryl ester transfer protein inhibitors in coronary heart disease: Validated comparative QSAR modeling of N, N-disubstituted trifluoro-3-amino-2-propanols.

312. Improved 3D-QSPR analysis of the predictive octanol–air partition coefficients of hydroxylated and methoxylated polybrominated diphenyl ethers.

313. Docking-based CoMFA and CoMSIA study of azaindole carboxylic acid derivatives as promising HIV-1 integrase inhibitors.

314. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

315. Exploring structural requirement and binding interactions of β-amyloid cleavage enzyme inhibitors using molecular modeling techniques.

316. Design of potent human steroid 5α-reductase inhibitors: 3D-QSAR CoMFA, CoMSIA and docking studies.

317. Molecular docking and 3D-QSAR studies on checkpoint kinase 1 inhibitors.

318. Pharmacophore modeling and 3D-QSAR (CoMSIA) studies for structural requirements of some triazine derivatives as G-quadruplex binders for telomerase inhibition.

319. Activity landscape analysis, CoMFA and CoMSIA studies of pyrazole CB1 antagonists.

320. Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1H-tetrazole derivatives as angiotensin II receptor type 1 (AT1) antagonists.

321. Combined 3D-QSAR modeling and molecular docking study on azacycles CCR5 antagonists.

322. Ligand-based CoMFA and CoMSIA studies on chromone derivatives as radical scavengers.

323. CoMFA and CoMSIA studies on C -aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents.

324. Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics.

325. Structural requirements of 3-carboxyl-4(1H)-quinolones as potential antimalarials from 2D and 3D QSAR analysis.

326. Development of robust QSAR model using rapid overlay of crystal structures (ROCS) based alignment: a test case of Tubulin inhibitors.

327. Docking and 3-D QSAR studies on the binding of tetrahydropyrimid-2-one HIV-1 protease inhibitors.

328. Three Dimensional Quantitative Structure-Activity Relationship of 5H-Pyrido[4,3-b]indol-4-carboxamide JAK2 Inhibitors.

329. A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors.

330. Comparative molecular similarity indices analysis of some 1-substituted imidazole analogs as Candida albicans P450-demethylase inhibitors.

331. Comparative molecular field analysis and comparative molecular similarity index analysis studies on 1H NMR chemical shift of NH group of diaryl triazene derivatives.

332. Enhancement of P-gylcoprotein modulators of arylmethylamine-phenyl derivatives: an integrative modeling approach.

333. 3D QSAR studies on 5-(2-methylbenzimidazol-1-yl)- N-alkylthiophene-2-carboxamide derivatives as P. falciparum dihydroorotate dehydrogenase ( PfDHODH) inhibitors.

334. Docking, CoMFA and CoMSIA studies of a series of sulfonamides derivatives as carbonic anhydrase I inhibitors.

335. THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP AND COMPARATIVE MOLECULAR FIELD ANALYSIS OF CYP450 ENZYME SYSTEM INHIBITORS.

336. 3D-QSAR, CoMFA, and CoMSIA of new phenyloxazolidinones derivatives as potent HIV-1 protease inhibitors.

337. A combined 3D QSAR and pharmacophore-based virtual screening for the identification of potent p38 MAP kinase inhibitors: an in silico approach.

338. Docking and CoMSIA studies on steroids and non-steroidal chemicals as androgen receptor ligands.

339. Triple-layered QSAR studies on substituted 1,2,4-trioxanes as potential antimalarial agents: superiority of the quantitative pharmacophore-based alignment over common substructure-based alignment.

340. Analysis of Ah receptor binding affinities of polybrominated diphenyl ethers via in silico molecular docking and 3D-QSAR.

341. Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach.

342. 3D-QSAR study of tyrosine and propanoic acid derivatives as PPARα/γ dual agonists using CoMSIA.

343. Three-dimensional quantitative structure-activity relationship (CoMSIA) analysis of bis-coumerine analogues as urease inhibitors.

344. 3D-QSAR studies of thiosemicarbazone and thiocarbamoylpyrazoline antiamebics.

345. Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure–activity relationships

346. Quantitative Studies on Structure-DPPH• Scavenging Activity Relationships of Food Phenolic Acids.

347. Classical and 3D QSAR studies on inverse agonists of human histamine H1 receptor.

348. Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents

349. A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of B-RAF inhibitors.

Catalog

Books, media, physical & digital resources